Do analysts rate MNPR or CNTN?

Monopar Therapeutics presently has a consensus price target of $108.75, indicating a potential downside of 6.77%. Given Monopar Therapeutics' stronger consensus rating and higher probable upside, research analysts clearly believe Monopar Therapeutics is more favorable than Hillstream Biopharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Monopar Therapeutics 1 Sell rating(s) 0 Hold rating(s) 10 Buy rating(s) 3 Strong Buy rating(s) 3.07 Hillstream Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better valuation & earnings, MNPR or CNTN?

Monopar Therapeutics is trading at a lower price-to-earnings ratio than Hillstream Biopharma, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Monopar Therapeutics N/A N/A -$13.72M -$1.90 N/A Hillstream Biopharma N/A N/A -$35.92M -$1.15 N/A

Is MNPR or CNTN more profitable?

Monopar Therapeutics' return on equity of -12.84% beat Hillstream Biopharma's return on equity. Company Net Margins Return on Equity Return on Assets Monopar Therapeutics N/A -12.84% -12.57% Hillstream Biopharma N/A -31.50% -24.72%

Does the media refer more to MNPR or CNTN?

In the previous week, Monopar Therapeutics had 4 more articles in the media than Hillstream Biopharma. MarketBeat recorded 5 mentions for Monopar Therapeutics and 1 mentions for Hillstream Biopharma. Monopar Therapeutics' average media sentiment score of 0.65 beat Hillstream Biopharma's score of 0.00 indicating that Monopar Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Monopar Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Hillstream Biopharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend RLMD or CNTN?

Relmada Therapeutics presently has a consensus target price of $12.00, indicating a potential upside of 132.11%. Given Relmada Therapeutics' stronger consensus rating and higher possible upside, research analysts clearly believe Relmada Therapeutics is more favorable than Hillstream Biopharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Relmada Therapeutics 1 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 2.75 Hillstream Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better earnings & valuation, RLMD or CNTN?

Relmada Therapeutics is trading at a lower price-to-earnings ratio than Hillstream Biopharma, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Relmada Therapeutics N/A N/A -$57.38M -$1.09 N/A Hillstream Biopharma N/A N/A -$35.92M -$1.15 N/A

Is RLMD or CNTN more profitable?

Hillstream Biopharma's return on equity of -31.50% beat Relmada Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Relmada Therapeutics N/A -71.22% -64.46% Hillstream Biopharma N/A -31.50% -24.72%

Does the media prefer RLMD or CNTN?

In the previous week, Relmada Therapeutics had 2 more articles in the media than Hillstream Biopharma. MarketBeat recorded 3 mentions for Relmada Therapeutics and 1 mentions for Hillstream Biopharma. Relmada Therapeutics' average media sentiment score of 0.65 beat Hillstream Biopharma's score of 0.00 indicating that Relmada Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Relmada Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Hillstream Biopharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer CNTN or ALLO?

Allogene Therapeutics has a consensus price target of $8.52, indicating a potential upside of 361.66%. Given Allogene Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Allogene Therapeutics is more favorable than Hillstream Biopharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Hillstream Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Allogene Therapeutics 1 Sell rating(s) 3 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 2.69

Which has preferable valuation and earnings, CNTN or ALLO?

Allogene Therapeutics is trading at a lower price-to-earnings ratio than Hillstream Biopharma, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Hillstream Biopharma N/A N/A -$35.92M -$1.15 N/A Allogene Therapeutics N/A N/A -$190.89M -$0.77 N/A

Is CNTN or ALLO more profitable?

Hillstream Biopharma's return on equity of -31.50% beat Allogene Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Hillstream Biopharma N/A -31.50% -24.72% Allogene Therapeutics N/A -56.45% -40.36%

Does the media prefer CNTN or ALLO?

In the previous week, Allogene Therapeutics had 1 more articles in the media than Hillstream Biopharma. MarketBeat recorded 2 mentions for Allogene Therapeutics and 1 mentions for Hillstream Biopharma. Allogene Therapeutics' average media sentiment score of 0.13 beat Hillstream Biopharma's score of 0.00 indicating that Allogene Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Hillstream Biopharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Allogene Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer CNTN or RGNX?

REGENXBIO has a consensus target price of $23.82, suggesting a potential upside of 134.64%. Given REGENXBIO's stronger consensus rating and higher possible upside, analysts clearly believe REGENXBIO is more favorable than Hillstream Biopharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Hillstream Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 REGENXBIO 2 Sell rating(s) 1 Hold rating(s) 10 Buy rating(s) 0 Strong Buy rating(s) 2.62

Does the media prefer CNTN or RGNX?

In the previous week, REGENXBIO had 10 more articles in the media than Hillstream Biopharma. MarketBeat recorded 11 mentions for REGENXBIO and 1 mentions for Hillstream Biopharma. REGENXBIO's average media sentiment score of 0.21 beat Hillstream Biopharma's score of 0.00 indicating that REGENXBIO is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Hillstream Biopharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral REGENXBIO 3 Very Positive mention(s) 1 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer CRMD or CNTN?

CorMedix currently has a consensus price target of $14.86, indicating a potential upside of 82.72%. Given CorMedix's stronger consensus rating and higher possible upside, equities analysts clearly believe CorMedix is more favorable than Hillstream Biopharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score CorMedix 0 Sell rating(s) 2 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.75 Hillstream Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Does the media refer more to CRMD or CNTN?

In the previous week, CorMedix had 1 more articles in the media than Hillstream Biopharma. MarketBeat recorded 2 mentions for CorMedix and 1 mentions for Hillstream Biopharma. CorMedix's average media sentiment score of 0.67 beat Hillstream Biopharma's score of 0.00 indicating that CorMedix is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CorMedix 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Hillstream Biopharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Hillstream Biopharma (CNTN) Competitors

$2.13 -0.03 (-1.34%)

As of 09:45 AM Eastern

Compare

CNTN vs. MNPR, RLMD, ALLO, RGNX, and CRMD

Should you buy Hillstream Biopharma stock or one of its competitors? MarketBeat compares Hillstream Biopharma with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Hillstream Biopharma include Monopar Therapeutics (MNPR), Relmada Therapeutics (RLMD), Allogene Therapeutics (ALLO), REGENXBIO (RGNX), and CorMedix (CRMD). These companies are all part of the "pharmaceutical products" industry.

How does Hillstream Biopharma compare to Monopar Therapeutics?

Monopar Therapeutics (NASDAQ:MNPR) and Hillstream Biopharma (NASDAQ:CNTN) are both small-cap pharmaceutical products companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, media sentiment, earnings, institutional ownership, valuation, profitability, risk and dividends.

Monopar Therapeutics has a beta of 1.46, indicating that its stock price is 46% more volatile than the broader market. Comparatively, Hillstream Biopharma has a beta of 1.42, indicating that its stock price is 42% more volatile than the broader market.

Monopar Therapeutics' return on equity of -12.84% beat Hillstream Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Monopar Therapeutics	N/A	-12.84%	-12.57%
Hillstream Biopharma	N/A	-31.50%	-24.72%

Monopar Therapeutics is trading at a lower price-to-earnings ratio than Hillstream Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Monopar Therapeutics	N/A	N/A	-$13.72M	-$1.90	N/A
Hillstream Biopharma	N/A	N/A	-$35.92M	-$1.15	N/A

1.8% of Monopar Therapeutics shares are owned by institutional investors. Comparatively, 1.2% of Hillstream Biopharma shares are owned by institutional investors. 9.7% of Monopar Therapeutics shares are owned by company insiders. Comparatively, 3.3% of Hillstream Biopharma shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Monopar Therapeutics presently has a consensus price target of $108.75, indicating a potential downside of 6.77%. Given Monopar Therapeutics' stronger consensus rating and higher probable upside, research analysts clearly believe Monopar Therapeutics is more favorable than Hillstream Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Monopar Therapeutics	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	3 Strong Buy rating(s)	3.07
Hillstream Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Monopar Therapeutics had 4 more articles in the media than Hillstream Biopharma. MarketBeat recorded 5 mentions for Monopar Therapeutics and 1 mentions for Hillstream Biopharma. Monopar Therapeutics' average media sentiment score of 0.65 beat Hillstream Biopharma's score of 0.00 indicating that Monopar Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Monopar Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Hillstream Biopharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Monopar Therapeutics beats Hillstream Biopharma on 12 of the 14 factors compared between the two stocks.

How does Hillstream Biopharma compare to Relmada Therapeutics?

Relmada Therapeutics (NASDAQ:RLMD) and Hillstream Biopharma (NASDAQ:CNTN) are both small-cap pharmaceutical products companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, dividends, risk, earnings, profitability, media sentiment and valuation.

In the previous week, Relmada Therapeutics had 2 more articles in the media than Hillstream Biopharma. MarketBeat recorded 3 mentions for Relmada Therapeutics and 1 mentions for Hillstream Biopharma. Relmada Therapeutics' average media sentiment score of 0.65 beat Hillstream Biopharma's score of 0.00 indicating that Relmada Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Relmada Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Hillstream Biopharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Relmada Therapeutics is trading at a lower price-to-earnings ratio than Hillstream Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Relmada Therapeutics	N/A	N/A	-$57.38M	-$1.09	N/A
Hillstream Biopharma	N/A	N/A	-$35.92M	-$1.15	N/A

45.2% of Relmada Therapeutics shares are owned by institutional investors. Comparatively, 1.2% of Hillstream Biopharma shares are owned by institutional investors. 14.5% of Relmada Therapeutics shares are owned by company insiders. Comparatively, 3.3% of Hillstream Biopharma shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Relmada Therapeutics presently has a consensus target price of $12.00, indicating a potential upside of 132.11%. Given Relmada Therapeutics' stronger consensus rating and higher possible upside, research analysts clearly believe Relmada Therapeutics is more favorable than Hillstream Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Relmada Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75
Hillstream Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Relmada Therapeutics has a beta of 0.41, indicating that its share price is 59% less volatile than the broader market. Comparatively, Hillstream Biopharma has a beta of 1.42, indicating that its share price is 42% more volatile than the broader market.

Hillstream Biopharma's return on equity of -31.50% beat Relmada Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Relmada Therapeutics	N/A	-71.22%	-64.46%
Hillstream Biopharma	N/A	-31.50%	-24.72%

Summary

Relmada Therapeutics beats Hillstream Biopharma on 9 of the 14 factors compared between the two stocks.

How does Hillstream Biopharma compare to Allogene Therapeutics?

Hillstream Biopharma (NASDAQ:CNTN) and Allogene Therapeutics (NASDAQ:ALLO) are both small-cap pharmaceutical products companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, analyst recommendations, valuation, profitability, earnings, dividends and risk.

Allogene Therapeutics is trading at a lower price-to-earnings ratio than Hillstream Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Hillstream Biopharma	N/A	N/A	-$35.92M	-$1.15	N/A
Allogene Therapeutics	N/A	N/A	-$190.89M	-$0.77	N/A

In the previous week, Allogene Therapeutics had 1 more articles in the media than Hillstream Biopharma. MarketBeat recorded 2 mentions for Allogene Therapeutics and 1 mentions for Hillstream Biopharma. Allogene Therapeutics' average media sentiment score of 0.13 beat Hillstream Biopharma's score of 0.00 indicating that Allogene Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Hillstream Biopharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Allogene Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Hillstream Biopharma has a beta of 1.42, suggesting that its stock price is 42% more volatile than the broader market. Comparatively, Allogene Therapeutics has a beta of 0.46, suggesting that its stock price is 54% less volatile than the broader market.

Allogene Therapeutics has a consensus price target of $8.52, indicating a potential upside of 361.66%. Given Allogene Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Allogene Therapeutics is more favorable than Hillstream Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Hillstream Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Allogene Therapeutics	1 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.69

Hillstream Biopharma's return on equity of -31.50% beat Allogene Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Hillstream Biopharma	N/A	-31.50%	-24.72%
Allogene Therapeutics	N/A	-56.45%	-40.36%

1.2% of Hillstream Biopharma shares are owned by institutional investors. Comparatively, 83.6% of Allogene Therapeutics shares are owned by institutional investors. 3.3% of Hillstream Biopharma shares are owned by insiders. Comparatively, 13.2% of Allogene Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Allogene Therapeutics beats Hillstream Biopharma on 9 of the 14 factors compared between the two stocks.

How does Hillstream Biopharma compare to REGENXBIO?

Hillstream Biopharma (NASDAQ:CNTN) and REGENXBIO (NASDAQ:RGNX) are both small-cap pharmaceutical products companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, dividends, risk, profitability, institutional ownership, valuation, analyst recommendations and media sentiment.

Hillstream Biopharma has higher earnings, but lower revenue than REGENXBIO. Hillstream Biopharma is trading at a lower price-to-earnings ratio than REGENXBIO, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Hillstream Biopharma	N/A	N/A	-$35.92M	-$1.15	N/A
REGENXBIO	$170.44M	3.08	-$193.88M	-$5.60	N/A

In the previous week, REGENXBIO had 10 more articles in the media than Hillstream Biopharma. MarketBeat recorded 11 mentions for REGENXBIO and 1 mentions for Hillstream Biopharma. REGENXBIO's average media sentiment score of 0.21 beat Hillstream Biopharma's score of 0.00 indicating that REGENXBIO is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Hillstream Biopharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
REGENXBIO	3 Very Positive mention(s)	1 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

REGENXBIO has a consensus target price of $23.82, suggesting a potential upside of 134.64%. Given REGENXBIO's stronger consensus rating and higher possible upside, analysts clearly believe REGENXBIO is more favorable than Hillstream Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Hillstream Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
REGENXBIO	2 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.62

Hillstream Biopharma has a net margin of 0.00% compared to REGENXBIO's net margin of -330.23%. Hillstream Biopharma's return on equity of -31.50% beat REGENXBIO's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Hillstream Biopharma	N/A	-31.50%	-24.72%
REGENXBIO	-330.23%	-232.50%	-61.02%

Hillstream Biopharma has a beta of 1.42, suggesting that its share price is 42% more volatile than the broader market. Comparatively, REGENXBIO has a beta of 0.9, suggesting that its share price is 10% less volatile than the broader market.

1.2% of Hillstream Biopharma shares are owned by institutional investors. Comparatively, 88.1% of REGENXBIO shares are owned by institutional investors. 3.3% of Hillstream Biopharma shares are owned by company insiders. Comparatively, 14.2% of REGENXBIO shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

REGENXBIO beats Hillstream Biopharma on 9 of the 15 factors compared between the two stocks.

How does Hillstream Biopharma compare to CorMedix?

CorMedix (NASDAQ:CRMD) and Hillstream Biopharma (NASDAQ:CNTN) are both small-cap pharmaceutical products companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, media sentiment, profitability, earnings and valuation.

CorMedix has a beta of 1.48, meaning that its share price is 48% more volatile than the broader market. Comparatively, Hillstream Biopharma has a beta of 1.42, meaning that its share price is 42% more volatile than the broader market.

CorMedix currently has a consensus price target of $14.86, indicating a potential upside of 82.72%. Given CorMedix's stronger consensus rating and higher possible upside, equities analysts clearly believe CorMedix is more favorable than Hillstream Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CorMedix	0 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.75
Hillstream Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, CorMedix had 1 more articles in the media than Hillstream Biopharma. MarketBeat recorded 2 mentions for CorMedix and 1 mentions for Hillstream Biopharma. CorMedix's average media sentiment score of 0.67 beat Hillstream Biopharma's score of 0.00 indicating that CorMedix is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CorMedix	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Hillstream Biopharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

CorMedix has higher revenue and earnings than Hillstream Biopharma. Hillstream Biopharma is trading at a lower price-to-earnings ratio than CorMedix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CorMedix	$311.71M	2.05	$163.05M	$2.13	3.82
Hillstream Biopharma	N/A	N/A	-$35.92M	-$1.15	N/A

CorMedix has a net margin of 45.25% compared to Hillstream Biopharma's net margin of 0.00%. CorMedix's return on equity of 45.57% beat Hillstream Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CorMedix	45.25%	45.57%	24.76%
Hillstream Biopharma	N/A	-31.50%	-24.72%

34.2% of CorMedix shares are owned by institutional investors. Comparatively, 1.2% of Hillstream Biopharma shares are owned by institutional investors. 3.5% of CorMedix shares are owned by company insiders. Comparatively, 3.3% of Hillstream Biopharma shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

CorMedix beats Hillstream Biopharma on 15 of the 15 factors compared between the two stocks.

Get Hillstream Biopharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CNTN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CNTN vs. The Competition

Export

Metric	Hillstream Biopharma	Pharmaceutical Preparations Industry	Manufacturing Sector	NASDAQ Exchange
Market Cap	$167.35M	$954.31M	$4.45B	$12.32B
Dividend Yield	N/A	4.84%	40.17%	9.67%
P/E Ratio	-1.89	1.52	23.71	24.18
Price / Sales	N/A	107.91	165.96	76.76
Price / Cash	N/A	20.06	163.97	59.37
Price / Book	0.20	8.83	13.41	6.25
Net Income	-$35.92M	-$2.87M	$120.21M	$331.66M
7 Day Performance	-10.84%	3.86%	-0.87%	-1.33%
1 Month Performance	-33.61%	5.85%	-2.15%	-1.75%
1 Year Performance	N/A	33.75%	10.55%	18.04%

Hillstream Biopharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CNTN Hillstream Biopharma	0.2331 of 5 stars	$2.13 -1.3%	N/A	N/A	$167.35M	N/A	N/A	2	Gap Up
MNPR Monopar Therapeutics	1.1912 of 5 stars	$99.79 -3.4%	$108.75 +9.0%	+144.6%	$692.21M	N/A	N/A	10	High Trading Volume
RLMD Relmada Therapeutics	2.5617 of 5 stars	$6.21 -3.7%	$12.00 +93.2%	+763.2%	$676.54M	N/A	N/A	10
ALLO Allogene Therapeutics	1.6698 of 5 stars	$1.85 -4.1%	$8.52 +360.7%	+40.2%	$666.15M	$20K	N/A	310	Positive News
RGNX REGENXBIO	3.6238 of 5 stars	$12.29 -3.6%	$23.82 +93.8%	+21.8%	$659.15M	$170.44M	N/A	370

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CNTN) was last updated on 7/22/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Hillstream Biopharma (CNTN) Competitors

CNTN vs. MNPR, RLMD, ALLO, RGNX, and CRMD

How does Hillstream Biopharma compare to Monopar Therapeutics?

Summary

How does Hillstream Biopharma compare to Relmada Therapeutics?

Summary

How does Hillstream Biopharma compare to Allogene Therapeutics?

Summary

How does Hillstream Biopharma compare to REGENXBIO?

Summary

How does Hillstream Biopharma compare to CorMedix?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CNTN vs. The Competition

Hillstream Biopharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Hillstream Biopharma (CNTN) Competitors

CNTN vs. MNPR, RLMD, ALLO, RGNX, and CRMD

How does Hillstream Biopharma compare to Monopar Therapeutics?

Which has more risk and volatility, MNPR or CNTN?

Is MNPR or CNTN more profitable?

Which has better valuation & earnings, MNPR or CNTN?

Do insiders and institutionals believe in MNPR or CNTN?

Do analysts rate MNPR or CNTN?

Does the media refer more to MNPR or CNTN?

Summary

How does Hillstream Biopharma compare to Relmada Therapeutics?

Does the media prefer RLMD or CNTN?

Which has better earnings & valuation, RLMD or CNTN?

Do insiders and institutionals believe in RLMD or CNTN?

Do analysts recommend RLMD or CNTN?

Which has more risk and volatility, RLMD or CNTN?

Is RLMD or CNTN more profitable?

Summary

How does Hillstream Biopharma compare to Allogene Therapeutics?

Which has preferable valuation and earnings, CNTN or ALLO?

Does the media prefer CNTN or ALLO?

Which has more risk & volatility, CNTN or ALLO?

Do analysts prefer CNTN or ALLO?

Is CNTN or ALLO more profitable?

Do institutionals & insiders believe in CNTN or ALLO?

Summary

How does Hillstream Biopharma compare to REGENXBIO?

Which has higher valuation and earnings, CNTN or RGNX?

Does the media prefer CNTN or RGNX?

Do analysts prefer CNTN or RGNX?

Is CNTN or RGNX more profitable?

Which has more volatility & risk, CNTN or RGNX?

Do institutionals and insiders hold more shares of CNTN or RGNX?

Summary

How does Hillstream Biopharma compare to CorMedix?

Which has more risk and volatility, CRMD or CNTN?

Do analysts prefer CRMD or CNTN?

Does the media refer more to CRMD or CNTN?

Which has higher earnings and valuation, CRMD or CNTN?

Is CRMD or CNTN more profitable?

Do institutionals & insiders believe in CRMD or CNTN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CNTN vs. The Competition

Hillstream Biopharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools